Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Akebia Therapeutics (AKBA) Misses Q1 EPS by 16c, Revenues Miss
May 10, 2021 8:10 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.45), $0.16 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $55.72 million.
"Akebia is off to a great start in 2021, building positive momentum with solid execution on strategic priorities that set the stage for an... More
